Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Bansback

Showing results (111-120 of 203) with videos related to

Pageof 21
Sort By:
RMD Open|June 28, 2019
Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HIIvette Essers, Mickael Hiligsmann, Uta Kiltz, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 26, 2014
Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea: A Case StudyLogan Trenaman, Mohsen Sadatsafavi, Fernanda Almeida, et al.
Pharmaceutical Statistics|April 3, 2009
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulationRichard M Nixon, Anthony O'Hagan, Jeremy Oakley, et al.
Rheumatology (Oxford, England)|December 20, 2011
Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RANick Bansback, Wei Zhang, David Walsh, et al.
Plos One|April 26, 2019
Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individualsMark Harrison, Luke Spooner, Nick Bansback, et al.
Arthritis Care & Research|February 8, 2023
Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series AnalysisAlison R McClean, Lucy Cheng, Nick Bansback, et al.
Arthritis and Rheumatism|June 26, 2008
Health state utility values: a description of their development and application for rheumatic diseasesNick Bansback, Mark Harrison, John Brazier, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 13, 2017
Testing and treatment for obstructive sleep apnea in Canada: funding models must changeSachin R Pendharkar, Marcus Povitz, Nick Bansback, et al.
Current Rheumatology Reports|July 29, 2017
Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable AnalysisNick Bansback, Eric Fu, Huiying Sun, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 15, 2016
How different are composite and traditional TTO valuations of severe EQ-5D-5L states?Feng Xie, Eleanor Pullenayegum, Kathy Gaebel, et al.
Pageof 21

Showing results (111-120 of 203) with videos related to

Sort By:
Pageof 21
RMD Open|June 28, 2019
Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HIIvette Essers, Mickael Hiligsmann, Uta Kiltz, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 26, 2014
Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea: A Case StudyLogan Trenaman, Mohsen Sadatsafavi, Fernanda Almeida, et al.
Pharmaceutical Statistics|April 3, 2009
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulationRichard M Nixon, Anthony O'Hagan, Jeremy Oakley, et al.
Rheumatology (Oxford, England)|December 20, 2011
Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RANick Bansback, Wei Zhang, David Walsh, et al.
Plos One|April 26, 2019
Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individualsMark Harrison, Luke Spooner, Nick Bansback, et al.
Arthritis Care & Research|February 8, 2023
Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series AnalysisAlison R McClean, Lucy Cheng, Nick Bansback, et al.
Arthritis and Rheumatism|June 26, 2008
Health state utility values: a description of their development and application for rheumatic diseasesNick Bansback, Mark Harrison, John Brazier, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 13, 2017
Testing and treatment for obstructive sleep apnea in Canada: funding models must changeSachin R Pendharkar, Marcus Povitz, Nick Bansback, et al.
Current Rheumatology Reports|July 29, 2017
Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable AnalysisNick Bansback, Eric Fu, Huiying Sun, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|February 15, 2016
How different are composite and traditional TTO valuations of severe EQ-5D-5L states?Feng Xie, Eleanor Pullenayegum, Kathy Gaebel, et al.
Pageof 21